<DOC>
	<DOCNO>NCT02593331</DOCNO>
	<brief_summary>This study evaluate safety tolerability profile BFKB8488A follow subcutaneous ( SC ) administration overweight obese subject ( body mass index [ BMI ] 27-40 kg/m^2 ) marker insulin resistance . Single ascend fix dos BFKB8488A evaluate . Participants randomize 7 sequential ascend fixed-dose cohort BFKB8488A SC placebo safety review perform escalation higher dose cohort .</brief_summary>
	<brief_title>Study Explore Safety , Tolerability Pharmacokinetics Subcutaneous Administration BFKB8488A Otherwise Healthy Overweight Obese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<criteria>Men woman age 18 65 . BMI &gt; 27.0 kg/m^2 &lt; =40 kg/m^2 AND BMI &gt; = 32 kg/m^2 OR HOMAIR &gt; 3.60 OR Waist circumference &gt; 100 cm ( male ) 88 cm ( female ) OR Fasting plasma insulin &gt; =15 mIU/L OR Fasting plasma glucose &gt; =100 mg/dl &lt; 126 mg/dl OR HbA1c &gt; 5.6 % &lt; 6.5 % . Negative pregnancy test . A diagnosis Type 2 diabetes mellitus time . Pregnant , lactate intend become pregnant study within 3 month study dose administer . Uncontrolled intercurrent illness psychiatric illness . Actively involved weight loss dietary program within last 6 month . History surgical procedure weight loss . History eat disorder . Uncontrolled hypertension ( systolic &gt; = 140 mmHg diastolic blood pressure &gt; = 90 mmHg ) either therapy screening Day 2 . Fasting triglyceride &gt; 500 mg/dL ( 5.64 mmol/L ) LDL &gt; 160 mg/dL ( 4.14 mmol/L ) screening . Any serious medical condition abnormality clinical laboratory test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>